Bayer Urges 9th Circ. Not To Revive Tevra Flea, Tick Meds Suit

By Editorial Team

Bayer is urging the Ninth Circuit not to grant a new trial over claims that it locked up the market for pet flea and tick treatment, saying the only evidence that rival Tevra showed a jury at trial was “highly dubious.”

The case involves a dispute between Bayer and Tevra over allegations of anticompetitive behavior related to flea and tick medications for pets. Bayer is pushing back against Tevra’s efforts to revive the lawsuit and is arguing that the evidence presented by Tevra during the trial is unreliable.

Bayer’s legal team, represented by law firms Arnold & Porter and Polsinelli PC, is making a strong case to the Ninth Circuit to uphold the previous trial’s decision and not allow a new trial to proceed.

On the other side, Tevra, represented by its legal counsel, is likely to continue fighting for a retrial, claiming that there are substantial grounds to challenge the initial verdict.

The case is being closely watched by legal experts and industry professionals as it could have significant implications for competition in the pet flea and tick medication market.

For more details on this ongoing legal battle, stay tuned for further updates as the Ninth Circuit considers Bayer’s request.